MedTrace Logo

Scotoma Reduction in AMD Patients Treated With Ranibizumab

NCT00467935 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-07-29

No results posted yet for this study

Summary

This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Conditions

  • Macular Degeneration

Interventions

DRUG

intravitreal injection Lucentis (ranibizumab)

intravitreal injection Lucentis (ranibizumab)

Sponsors & Collaborators

  • Retina Research Foundation

    lead OTHER

Principal Investigators

  • Paul M Beer, MD · Retina Research Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467935 on ClinicalTrials.gov